DEA Halts Move to Ban Controversial Herbal Kratom

Share this content:
DEA Halts Move to Ban Controversial Herbal Kratom
DEA Halts Move to Ban Controversial Herbal Kratom

FRIDAY, Oct. 14, 2016 (HealthDay News) -- Bowing to public pressure, the U.S. Drug Enforcement Administration has halted a move to ban a plant called kratom, which experts say could help battle the nation's opioid epidemic.

Kratom is a plant from southeast Asia that contains a number of substances that trigger effects similar to opiates when consumed. Some people claim that kratom helped them overcome opiate and alcohol addiction and to treat chronic pain. In a preliminary document posted to the Federal Register Thursday, the DEA announced withdrawal of its notice of intent to ban kratom and said it needs to obtain more research, the Washington Post reported.

Researchers say kratom may help them develop nonaddictive alternatives to opioids, but that a DEA ban on kratom would hinder those efforts, the Post reported. A number of U.S. lawmakers also opposed the DEA's move to ban kratom.

The DEA will accept public comment on krakom until Dec. 1 of this year and asked the U.S. Food and Drug Administration to expedite a "scientific and medical evaluation and scheduling recommendation" for the active chemical compounds in kratom, the Post reported. After the public comment period closes, the DEA could impose different levels of regulation on kratom or leave it unregulated.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »